Triple
T18213098
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Lugano classification |
E436081
|
entity |
| Predicate | recommends |
P488
|
FINISHED |
| Object | PET-CT as standard for FDG-avid lymphomas |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: PET-CT as standard for FDG-avid lymphomas | Statement: [Lugano classification, recommends, PET-CT as standard for FDG-avid lymphomas]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: PET-CT as standard for FDG-avid lymphomas Context triple: [Lugano classification, recommends, PET-CT as standard for FDG-avid lymphomas]
-
A.
non-Hodgkin lymphoma
Non-Hodgkin lymphoma is a diverse group of blood cancers that originate in the lymphatic system from abnormal lymphocytes and can vary widely in aggressiveness and prognosis.
-
B.
Hodgkin lymphoma
Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, characterized by the presence of abnormal Reed–Sternberg cells and often affecting lymph nodes.
-
C.
ABVD regimen
The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
-
D.
Leukemia and Lymphoma Research
Leukemia and Lymphoma Research is a UK-based medical research charity dedicated to improving the diagnosis, treatment, and prevention of blood cancers such as leukemia and lymphoma.
-
E.
Hodgkin
Hodgkin is a surname most famously associated with Dorothy Hodgkin, the Nobel Prize–winning British chemist who advanced the field of X-ray crystallography.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: PET-CT as standard for FDG-avid lymphomas Target entity description: PET-CT as standard for FDG-avid lymphomas refers to the use of fluorodeoxyglucose positron emission tomography combined with computed tomography as the primary imaging modality for staging and response assessment in lymphomas that avidly take up FDG.
-
A.
non-Hodgkin lymphoma
Non-Hodgkin lymphoma is a diverse group of blood cancers that originate in the lymphatic system from abnormal lymphocytes and can vary widely in aggressiveness and prognosis.
-
B.
Hodgkin lymphoma
Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, characterized by the presence of abnormal Reed–Sternberg cells and often affecting lymph nodes.
-
C.
ABVD regimen
The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
-
D.
Leukemia and Lymphoma Research
Leukemia and Lymphoma Research is a UK-based medical research charity dedicated to improving the diagnosis, treatment, and prevention of blood cancers such as leukemia and lymphoma.
-
E.
Hodgkin
Hodgkin is a surname most famously associated with Dorothy Hodgkin, the Nobel Prize–winning British chemist who advanced the field of X-ray crystallography.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b90dba6481908e119eb9aa4ca0cb |
completed | April 10, 2026, 8:47 a.m. |
| NER | Named-entity recognition | batch_69e4e22a26308190a6720b41a9bbfc2d |
completed | April 19, 2026, 2:09 p.m. |
Created at: April 10, 2026, 10:32 a.m.